2023-05-09 12:13:32 ET
- Cancer test makers iCAD ( NASDAQ: ICAD ) and Hologic ( NASDAQ: HOLX ) recorded sharp gains on Tuesday after the U.S. Preventive Services Task Force issued draft changes to breast cancer screening guidelines.
- Per the proposed guidelines, the task force recommends all women undergo mammography screening starting at age 40, ten years earlier than its previous recommendations.
- Mammography is a method for early detection of breast cancer where companies such as iCAD ( ICAD ), Hologic ( HOLX ), ENDRA Life Sciences ( NDRA ), GE Healthcare ( GEHC ), Boston Scientific ( BSX ), Stryker ( SYK ) and Siemens Healthineers ( OTCPK:SEMHF ) operate.
- The expert group, an influential player in public health recommendations, also advises women to continue breast cancer screenings every other year until they reach 74 years.
- The draft recommendations are available for public comments until June 05, 2023.
For further details see:
iCAD, Hologic gain after update on breast screening guidelines